Loss of efficacy over time (secondary failure), the need for higher doses for spine involvement, or paradoxical reactions associated with IL-17 inhibition similar to lupus-like syndrome or psoriasis after TNF inhibition [56,57] arise as possible explanations for these unexpected events. This evidence concerns the gene IL17A and drug-induced lupus erythematosus.